IGM Biosciences, Inc. (IGMS)
| Market Cap | 76.57M |
| Revenue (ttm) | 145.05M +4,882.8% |
| Net Income | -53.39M |
| EPS | -0.88 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 1.300 |
| Day's Range | n/a |
| 52-Week Range | 0.920 - 22.500 |
| Beta | 0.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2025 |
About IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Financial Performance
In 2024, IGM Biosciences's revenue was $2.68 million, an increase of 25.77% compared to the previous year's $2.13 million. Losses were -$195.80 million, -20.54% less than in 2023.
Financial StatementsNews
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today...
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of Decembe...
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...
IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay
IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower thei...
IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases
The biotechnology company says it will focus only on autoimmune diseases.
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 –
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, C...
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases Agreement focuses on immunology/inflam...
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...
Medivir to present at the Carlsquare Equity Research Investor Day
STOCKHOLM , Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All cli...
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
STOCKHOLM , Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The ...
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
STOCKHOLM , Nov. 27, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
Medivir to present at the Redeye Life Science Day
STOCKHOLM , Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
Medivir to present at the Erik Penser Bank Company Event
STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
IGM Biosciences Announces Third Quarter 2023 Financial Results
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Bioscien...